ALS Limited (FRA:CP4)

Revenue by Segment

Financials in millions AUD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Commodities	1.09B	1.09B	1.09B	886.50M	624.80M
Commodities Growth	0.22%	-0.05%	22.63%	41.89%	-2.71%
Life Sciences	1.91B	1.38B	-	-	930.00M
Life Sciences Growth	38.94%	-	-	-	-3.25%
Life Sciences Excl Nuvisan	-	-	1.19B	1.07B	-
Life Sciences Excl Nuvisan Growth	-	-	11.90%	-	-
Elimination Nuvisan	-	-	-142.00M	-73.80M	-
Life Sciences - Nuvisan	-	-	142.00M	73.80M	-
Life Sciences - Nuvisan Growth	-	-	92.41%	-	-
Industrial	-	-	-	-	206.60M
Industrial Growth	-	-	-	-	-17.52%
Total	3.00B	2.46B	2.28B	1.95B	1.76B
Total Growth	21.85%	8.00%	16.77%	10.81%	-4.99%

Revenue by Geography

Financials in millions AUD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Africa	65.50M	57.60M	54.50M	45.50M	34.70M
Africa Growth	13.72%	5.69%	19.78%	31.12%	-25.54%
Asia/Pacific	854.10M	810.10M	764.60M	647.20M	672.40M
Asia/Pacific Growth	5.43%	5.95%	18.14%	-3.75%	-0.53%
Americas	1.03B	999.80M	945.70M	780.30M	588.40M
Americas Growth	3.45%	5.72%	21.20%	32.61%	-15.14%
EMENA (Europe, Middle East, North Africa)	1.05B	594.10M	514.50M	478.90M	465.90M
EMENA (Europe, Middle East, North Africa) Growth	75.98%	15.47%	7.43%	2.79%	6.39%
Total	3.00B	2.46B	2.28B	1.95B	1.76B
Total Growth	21.85%	8.00%	16.77%	10.82%	-4.99%

Source: S&P Global Market Intelligence.